These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7231653)

  • 1. Use of naloxone in schizophrenic psychoses and manic syndromes.
    Verhoeven WM; van Praag HM; de Jong JT
    Neuropsychobiology; 1981; 7(3):159-68. PubMed ID: 7231653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study.
    Pickar D; Vartanian F; Bunney WE; Maier HP; Gastpar MT; Prakash R; Sethi BB; Lideman R; Belyaev BS; Tsutsulkovskaja MV; Jungkunz G; Nedopil N; Verhoeven W; van Praag H
    Arch Gen Psychiatry; 1982 Mar; 39(3):313-9. PubMed ID: 6121545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of naloxone to reduce manic symptoms.
    Davis GC; Extein I; Reus VI; Hamilton W; Post RM; Goodwin FK; Bunney WE
    Am J Psychiatry; 1980 Dec; 137(12):1583-5. PubMed ID: 7435717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of naloxone with schizophrenic and manic patients.
    Sethi BB; Prakash R
    Br J Psychiatry; 1981 Jun; 138():501-3. PubMed ID: 7028200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Administration of naloxone in schizophrenic psychoses and manic syndromes].
    Verhoeven WM; van Praag HM; de Jong JT
    Ned Tijdschr Geneeskd; 1981 Apr; 125(14):532-7. PubMed ID: 6112715
    [No Abstract]   [Full Text] [Related]  

  • 6. Behavioral effects of opioid receptor antagonists in psychopathologic states.
    Janowsky DS; Judd LL; Huey LY; Risch SC; Segal DS
    Psychiatr Clin North Am; 1983 Sep; 6(3):403-14. PubMed ID: 6316300
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of naloxone on schizophrenia: reduction in hallucinations in a subpopulation of subjects.
    Watson SJ; Berger PA; Akil H; Mills MJ; Barchas JD
    Science; 1978 Jul; 201(4350):73-6. PubMed ID: 351804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some observations on the opiate peptides and schizophrenia.
    Watson SJ; Akil H; Berger PA; Barchas JD
    Arch Gen Psychiatry; 1979 Jan; 36(1):35-41. PubMed ID: 216330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Action of naloxone and naltrexone in different types of psychoses.
    Volavka J
    Mod Probl Pharmacopsychiatry; 1981; 17():202-12. PubMed ID: 6276726
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of narcotics and narcotic antagonists on affective disorders, schizophrenia and serum neurohormones.
    Judd LL; Janowsky DS
    Mod Probl Pharmacopsychiatry; 1981; 17():213-25. PubMed ID: 6120452
    [No Abstract]   [Full Text] [Related]  

  • 11. Repeated naloxone administration in schizophrenia.
    Verhoeven WM; van Praag HM; van Ree JM
    Psychiatry Res; 1984 Aug; 12(4):297-312. PubMed ID: 6594713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of naloxone on the state of patients with endogenous psychoses.
    Lideman RR; Panteleeva GP; Tsutsul'kovskaya MYa ; Vartanyan FE; Belyaev BS
    Neurosci Behav Physiol; 1984; 14(6):471-5. PubMed ID: 6097836
    [No Abstract]   [Full Text] [Related]  

  • 13. Behavioral and neuroendocrine effects of opioid receptor agonists in psychopathologic states.
    Judd LL; Risch SC; Segal DS; Janowsky DS; Huey LY
    Psychiatr Clin North Am; 1983 Sep; 6(3):393-402. PubMed ID: 6359090
    [No Abstract]   [Full Text] [Related]  

  • 14. [Etiologic and therapeutic significance of endorphins in endogenous psychoses].
    Naber D
    Nervenarzt; 1983 Nov; 54(11):573-7. PubMed ID: 6318141
    [No Abstract]   [Full Text] [Related]  

  • 15. The effects of naloxone in chronic schizophrenia.
    Berger PA; Watson SJ; Akil H; Barchas JD
    Am J Psychiatry; 1981 Jul; 138(7):913-8. PubMed ID: 6266259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of schizophrenic psychoses with gamma-type endorphins.
    van Praag HM; Verhoeven WM; van Ree JM; de Wied D
    Biol Psychiatry; 1982 Jan; 17(1):83-98. PubMed ID: 6174158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative naloxone effects in schizophrenic patients.
    Janowsky DS; Segal DS; Abrams A; Bloom F; Guillemin R
    Psychopharmacology (Berl); 1977 Aug; 53(3):295-7. PubMed ID: 19807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic properties of Des-enkephalin-gamma-endorphin in treatment of schizophrenic patients.
    Verhoeven WM; van Ree JM; Heezius-van Bentum A; de Wied D; van Praag HM
    Arch Gen Psychiatry; 1982 Jun; 39(6):648-54. PubMed ID: 7092498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research in endorphins and schizophrenia.
    Davis GC; Buchsbaum MS; Bunney WE
    Schizophr Bull; 1979; 5(2):244-50. PubMed ID: 37596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous naloxone administration in schizophrenia and affective illness.
    Davis GC; Bunney WE; DeFraites EG; Kleinman JE; van Kammen DP; Post RM; Wyatt RJ
    Science; 1977 Jul; 197(4298):74-7. PubMed ID: 325650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.